Sugi Predict

Sugi Predict / Compounds / SCHEMBL19964151

SCHEMBL19964151

SCHEMBL19964151

CC(C)(C)OC(=O)N1CC(O[Si](C)(C)C(C)(C)C)C[C@@H]1CO

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.42
▸ SRC P12931 8/20 0.39
▸ ABCB1 P08183 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ USP2 O75604 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2386707 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL21286125 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL1241324 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL1241323 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL142689 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL139880 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL20312947 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL1372634 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL30868937 0.97 NR1H2 (0.40) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL6577745 0.92 NR1H2 (0.41) NR1H2SRCMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024015731-A1 FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS INCYTE CORPORATION (US) 2024-01-18 — — WO disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
WO-2022272020-A1 IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-12-29 — — WO disclosed
US-10689377-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-06-23 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885SRC 628/4885ABCB1 797/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS NR1H2 1539/4885SRC 628/4885ABCB1 797/4885
US-10689377-B2 KRas G12C inhibitors KRAS, NRAS, HRAS NR1H2 1539/4885SRC 628/4885ABCB1 797/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885SRC 628/4885ABCB1 797/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885SRC 628/4885ABCB1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.